Zacks Research Issues Optimistic Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Research analysts at Zacks Research increased their Q1 2026 earnings estimates for shares of Agilent Technologies in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the medical research company will earn $1.39 per share for the quarter, up from their prior estimate of $1.35. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.47 EPS.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%.

A has been the topic of a number of other reports. Robert W. Baird cut their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, November 26th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $135.00 to $145.00 in a report on Monday, February 10th. Bank of America decreased their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Sanford C. Bernstein dropped their price target on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $146.15.

Agilent Technologies Stock Down 1.3 %

Shares of NYSE:A opened at $120.35 on Monday. Agilent Technologies has a 1 year low of $117.17 and a 1 year high of $155.35. The company has a market capitalization of $34.31 billion, a PE ratio of 27.67, a price-to-earnings-growth ratio of 3.39 and a beta of 1.11. The business has a fifty day moving average price of $135.88 and a two-hundred day moving average price of $137.05. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66.

Hedge Funds Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Flynn Zito Capital Management LLC increased its position in shares of Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company’s stock valued at $251,000 after purchasing an additional 69 shares during the last quarter. IFP Advisors Inc boosted its stake in Agilent Technologies by 17.7% in the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock worth $62,000 after buying an additional 69 shares in the last quarter. Tiemann Investment Advisors LLC grew its position in Agilent Technologies by 5.6% during the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company’s stock valued at $191,000 after acquiring an additional 75 shares during the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Agilent Technologies by 13.5% during the third quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock worth $96,000 after acquiring an additional 77 shares in the last quarter. Finally, Rothschild Investment LLC lifted its holdings in shares of Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock worth $66,000 after acquiring an additional 79 shares during the last quarter.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s payout ratio is 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.